Serum paraoxonase activity and oxidative stress in patients with adult nephrotic syndrome

Atherosclerosis

Volumn 218, Issue 1, 2011, Pages 243-246

  Soyoral, Yasemin Usul ^a   Aslan, Mehmet ^a   Emre, Habib ^a   Begenik, Huseyin ^a   Erdur, Fatih Mehmet ^a   Turkel, Adnan ^a   Selek, Sahbettin ^b   Erkoc, Reha ^a  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

^b HARRAN UNIVERSITY   (Turkey)

Author keywords

Atherosclerosis; Lipid hydroperoxide; Nephrotic syndrome; PON1 activity; Total thiol

Indexed keywords

ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; LIPID HYDROPEROXIDE; OXIDIZING AGENT; THIOL;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MALE; NEPHROTIC SYNDROME; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEINURIA; RISK FACTOR;

ADULT; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; BIOPSY; CARBOXYLIC ESTER HYDROLASES; FEMALE; HUMANS; LIPID PEROXIDES; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; OXIDANTS; OXIDATIVE STRESS; PROSPECTIVE STUDIES; PROTEINURIA; SULFHYDRYL COMPOUNDS;

EID: 80052261579     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.05.037     Document Type: Article

References (45)

1. Dogra G., Ward N., Croft K.D., et al. Oxidant stress in nephrotic syndrome: comparison of F(2)-isoprostanes and plasma antioxidant potential. Nephrol Dial Transplant 2001, 16(8):1626-1630.
2. Ueda N., Baliga R., Shah S.V. Role of catalytic iron in an animal model of minimal change nephrotic syndrome. Kidney Int 1996, 49:370-373.
3. Ohtake T., Kimura M., Nishimura M., Hishida A. Roles of reactive oxygen species and antioxidant enzymes in murine daunomycin-induced nephropathy. J Lab Clin Med 1997, 129:81-88.
4. Clemens M.R., Burza-Zanetti Z. Lipid abnormalities and peroxidation of erythrocytes in nephrotic syndrome. Nephron 1989, 53:325-329.
5. Savin V.J. Mechanisms of proteinuria in noninflammatory glomerular diseases. Am J Kidney Dis 1993, 21:347-362.
6. Yoshioka T., Ichikawa J., Fogo A. Reactive oxygen metabolites cause massive, reversible proteinuria and glomerular sieving defect without apparent ultrastructural abnormality. J Am Soc Nephrol 1991, 2:902-912.
7. Granqvist A., Nilsson U.A., Ebefors K., Haraldsson B., Nyström J. Impaired glomerular and tubular antioxidative defense mechanisms in nephrotic syndrome. Am J Physiol Renal Physiol 2010, 299(4):898-904.
8. Gupta V.K., Mallika V., Gupta Y., Srivastava D.K. Oxygen derived free radicals in clinical context. Ind J Clin Biochem 1992, 7:3-10.
9. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 632:801-809.
10. Guijarro C., Keane W.F. Lipid-induced glomerular injury. Nephron 1994, 67:1-6.
11. Skrzep-Poloczek B., Tomasik A., Tarnawski R., et al. Nephrotic origin hyperlipidemia, relative reduction of vitamin E level and subsequent oxidative stress may promote atherosclerosis. Nephron 2001, 89(1):68-72.
12. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004, 37:112-119.
13. Durrington P.N., Mackness B., Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001, 21:473-480.
14. Witztum J.L. The oxidation hypothesis of atherosclerosis. Lancet 1994, 344:793-795.
15. Ng C.J., Shih D.M., Hama S.Y., Villa N., Navab M., Reddy S.T. The paraoxonase gene family and atherosclerosis. Free Radic Biol Med 2005, 38:153-163.
16. Watson A.D., Berliner J.A., Hama S.Y., et al. Protective effect of high density lipoprotein associated paraoxonase: inhibitition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995, 96:2882-2891.
17. Mackness M.I., Abbott C., Arrol S., Durrington P.N. The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 1993, 294:829-834.
18. Parthasarathy S., Barnett J., Fong L.G. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990, 1044:275-283.
19. Aviram M., Rosenblat M., Billecke S., et al. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999, 26:892-904.
20. Kabaroglu C., Mutaf I., Boydak B., et al. Association between serum paraoxonase activity and oxidative stress in acute coronary syndromes. Acta Cardiol 2004, 59:606-611.
21. Frishberg Y., Toledano H., Becker-Cohen R., Feigin E., Halle D. Genetic polymorphism in paraoxonase is a risk factor for childhood focal segmental glomerulosclerosis. Am J Kidney Dis 2000, 36:1253-1261.
22. Gullulu M., Kahvecioglu S., Dirican M., et al. Paraoxonase activity in glomerulonephritic patients. Ren Fail 2007, 29:433-439.
23. Ece A., Atamer Y., Gurkan F., Davutoĝlu M., Kocyigit Y., Tutanc M. Paraoxonase, total antioxidant response, and peroxide levels in children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 2005, 20:1279-1284.
24. Sodergren E., Nourooz-Zadeh J., Berglund L., Vessby B. Re-evaluation of the ferrous oxidation in xylenol orange assay for the measurement of plasma lipid hydroperoxides. J Biochem Biophys Methods 1998, 37(3):137-146.
25. Eckerson H.W., Wyte C.M., La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983, 35:1126-1138.
26. Haagen L., Brock A. A new automated method for phenotyping arylesterase (E.C. 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 1992, 30:391-395.
27. Nourooz Zadeh J. Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma. Methods Enzymol 1999, 300:58-62.
28. Hu M.L., Louie S., Cross C.E., Motchnik P., Halliwell B. Antioxidant protection against hypochlorous acid in human plasma. J Lab Clin Med 1993, 121:257-262.
29. Alfrey A.C. Role of iron and oxygen radicals in the progression of chronic renal failure. Am J Kidney Dis 1994, 23:183-187.
30. Diamond J.R. The role of reactive oxygen species in animal models of glomerular disease. Am J Kidney Dis 1992, 19:292-300.
31. Yoshioka T., Bills T., Moore-Jarrett T., Greene H.L., Burr I.M., Ichikawa I. Role of intrinsic antioxidant enzymes in renal oxidant injury. Kidney Int 1990, 38:232-238.
32. Zima T., Tesar V., Stipek S. The influence of cyclosporine on lipid peroxidation and superoxide dismutase in adriamycin nephropathy in rats. Nephron 1997, 75:464-469.
33. Girotti A.W. Lipid hydroperoxide generation, turnover, and effector action in biological systems. J Lipid Res 1998, 39:1529-1542.
34. Leitinger N. Cholesteryl ester oxidation products in atherosclerosis. Mol Aspects Med 2003, 24:239-250.
35. Aslan M., Kosecik M., Horoz M., Selek S., Celik H., Erel O. Assessment of paraoxonase and arylesterase activities in patients with iron deficiency anemia. Atherosclerosis 2007, 191:397-402.
36. Dirican M., Akca R., Sarandol E., Dilek K. Serum paraoxonase activity in uremic predialysis and hemodialysis patients. J Nephrol 2004, 17:813-818.
37. Serdar Z., Aslan K., Dirican M., Sarandol E., Yesilbursa D., Serdar A. Lipid and protein oxidation and antioxidant status in patients with angiographically proven coronary artery disease. Clin Biochem 2006, 39:794-803.
38. Mackness B., Durington P., McElduff P., et al. Low paraoxonase activity predicts coronary events in the caterphilly prospective study. Circulation 2003, 107:2775-2779.
39. Van der Gaag M.S., van Tol A., Scheek L.M., et al. Daily moderate alcohol consumption increases serum paraoxonase activity; a diet controlled, randomized intervention study in middle-aged men. Atherosclerosis 1999, 147:405-410.
40. Sutherland W.H., Walker R.J., de Jong S.A., van Rij A.M., Phillips V., Walker H.L. Reduced postprandial serum paraoxonase activity after meal rich in used cooking fat. Arterioscler Thromb Vasc Biol 1999, 19:1340-1347.
41. Chandra M., Chandra N., Agrawal R., Kumar A., Ghatak A., Pandey V.C. The free radical system in ischemic heart disease. Int J Cardiol 1994, 43:121-125.
42. Jarvik G.P., Tsai N.T., McKinstry L.A., et al. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol 2004, 22:1329-1333.
43. Rozenberg O., Aviram M. S-glutathionylation regulates HDL-associated paraoxonase 1 (PON1) activity. Biochem Biophys Res Commun 2006, 351:492-498.
44. Gur M., Aslan M., Yildiz A., et al. Paraoxonase and arylesterase activities in coronary artery disease. Eur J Clin Invest 2006, 36:779-787.
45. Mackness B., Davies G.K., Turkie W., et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?. Arterioscler Thromb Vasc Biol 2001, 21:1451-1457.